BACKGROUND Almost 80 percent of adults in the United States have had cytomegalovirus(CMV)infection by age 40.The number of symptomatic CMV hepatitis cases has been increasing along with non-alcoholic fatty liver disea...BACKGROUND Almost 80 percent of adults in the United States have had cytomegalovirus(CMV)infection by age 40.The number of symptomatic CMV hepatitis cases has been increasing along with non-alcoholic fatty liver disease(NAFLD)cases in the United States that is estimated to be 25 percent of the population.In this paper,we try to link these two entities together.CASE SUMMARY In this case report,we describe a young female who presented with fever,nausea,and vomiting who was found to have NAFLD and CMV hepatitis that was treated supportively.CONCLUSION In this case report,we describe NAFLD as a risk factor for CMV hepatitis and discuss the possible impact on clinical practice.We believe,it is essential to consider NAFLD and it’s disease mechanisms’localized immu-nosuppression,as a risk factor of CMV hepatitis and severe coronavirus disease 2019 infection.展开更多
Human cytomegalovirus (HCMV) infection is common and affects between 40–100% of the worldwide population. However, the majority of cases are asymptomatic and when severe disease occurs, it is usually restricted to im...Human cytomegalovirus (HCMV) infection is common and affects between 40–100% of the worldwide population. However, the majority of cases are asymptomatic and when severe disease occurs, it is usually restricted to immunocompromised patients. Liver involvement by HCMV differs significantly, accordingly to the immune status of the host. In immunocompromised patients, particularly liver transplant patients, it often causes clinically significant hepatitis. On the other hand, in immunocompetent patients, HCMV hepatitis requiring hospitalization is extremely rare. This review aims to appraise studies regarding the pathophysiology of HCMV hepatitis, including mechanisms of latency and reactivation and its contribution to disease development, clinical presentation, diagnostic modalities and treatment, with a focus on comparing different aspects between immunocompromised and immunocompetent hosts.展开更多
To demonstrate the anti-cytomegalovirus (CMV) activity of allitridin injection (AI), an active anti-infection component of garlic, the in vitro effects of AI on human CMV (HCMV) AD169 and 7 newly isolated strains from...To demonstrate the anti-cytomegalovirus (CMV) activity of allitridin injection (AI), an active anti-infection component of garlic, the in vitro effects of AI on human CMV (HCMV) AD169 and 7 newly isolated strains from patients and its in vivo effect on mice of murine CMV (MCMV) hepatitis were assessed. Itwas found that plaque reduction rate reached 63. 5 % after infected cells weretreated with cell maximal tolerable concentration (7. 5 μg/ml) of AI. Meanwhile,flow cytometric analysis for effect of AI on expression of HCMV immediate-earlyantigen (IEA) showed that IEA inhibition rate of 7 isolated strains was in the range from 43. 3% to 66. 7%, with a mean of 58. 4 %, similar to that of AD169strain (60. 5 %). On the other hand, in vivo anti-CMV activity of AI was evaluated in terms of liver pathological changes, liver function and viral replication. Six model mice with MCMV hepatitis received the treatment of AI for 2 weeks. The severity of liver damage, levels of sALT and MCMV IE genes expression in liver tissues in the treated mice were significantly lower than those of the corresponding untreated controls. Our results showed that AI had an obvious anti-CMV activity both in vitro and in vivo.展开更多
文摘BACKGROUND Almost 80 percent of adults in the United States have had cytomegalovirus(CMV)infection by age 40.The number of symptomatic CMV hepatitis cases has been increasing along with non-alcoholic fatty liver disease(NAFLD)cases in the United States that is estimated to be 25 percent of the population.In this paper,we try to link these two entities together.CASE SUMMARY In this case report,we describe a young female who presented with fever,nausea,and vomiting who was found to have NAFLD and CMV hepatitis that was treated supportively.CONCLUSION In this case report,we describe NAFLD as a risk factor for CMV hepatitis and discuss the possible impact on clinical practice.We believe,it is essential to consider NAFLD and it’s disease mechanisms’localized immu-nosuppression,as a risk factor of CMV hepatitis and severe coronavirus disease 2019 infection.
文摘Human cytomegalovirus (HCMV) infection is common and affects between 40–100% of the worldwide population. However, the majority of cases are asymptomatic and when severe disease occurs, it is usually restricted to immunocompromised patients. Liver involvement by HCMV differs significantly, accordingly to the immune status of the host. In immunocompromised patients, particularly liver transplant patients, it often causes clinically significant hepatitis. On the other hand, in immunocompetent patients, HCMV hepatitis requiring hospitalization is extremely rare. This review aims to appraise studies regarding the pathophysiology of HCMV hepatitis, including mechanisms of latency and reactivation and its contribution to disease development, clinical presentation, diagnostic modalities and treatment, with a focus on comparing different aspects between immunocompromised and immunocompetent hosts.
文摘To demonstrate the anti-cytomegalovirus (CMV) activity of allitridin injection (AI), an active anti-infection component of garlic, the in vitro effects of AI on human CMV (HCMV) AD169 and 7 newly isolated strains from patients and its in vivo effect on mice of murine CMV (MCMV) hepatitis were assessed. Itwas found that plaque reduction rate reached 63. 5 % after infected cells weretreated with cell maximal tolerable concentration (7. 5 μg/ml) of AI. Meanwhile,flow cytometric analysis for effect of AI on expression of HCMV immediate-earlyantigen (IEA) showed that IEA inhibition rate of 7 isolated strains was in the range from 43. 3% to 66. 7%, with a mean of 58. 4 %, similar to that of AD169strain (60. 5 %). On the other hand, in vivo anti-CMV activity of AI was evaluated in terms of liver pathological changes, liver function and viral replication. Six model mice with MCMV hepatitis received the treatment of AI for 2 weeks. The severity of liver damage, levels of sALT and MCMV IE genes expression in liver tissues in the treated mice were significantly lower than those of the corresponding untreated controls. Our results showed that AI had an obvious anti-CMV activity both in vitro and in vivo.
